Sign up
Pharma Capital

ANGLE PLC's Andrew Newland on 'very exciting' liquid biopsy breakthrough

Andrew Newland, chief executive of ANGLE PLC (LON:AGL,OTCQX:ANPCY) tells Proactive their Parsortix system, which is used to harvest circulating tumour cells from the blood stream associated with cancer, has helped researchers from the Queen Mary University of London's Barts Cancer Institute find two rare cells.

The study of 40 people found that combining them enabled the identification of patients who are 10-times more likely to die of prostate cancer in the short-term.

 

View full AGL profile

ANGLE plc Timeline

Newswire

ANGLE raises another £2.8mln

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.